Daniel O Clegg
Overview
Explore the profile of Daniel O Clegg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Williams H, Cannon G, Clegg D
Rheum Dis Clin North Am
. 2023 Nov;
50(1):113-121.
PMID: 37973279
John Robert Ward was one of the early academic rheumatologists in the United States. He was the founding father of rheumatology in the Intermountain West, the first Chief of the...
2.
Sawitzke A, Jackson C, Carlson K, Bizien M, Leiner M, Reda D, et al.
JAMA Netw Open
. 2022 Mar;
5(3):e220632.
PMID: 35258579
Importance: Osteoarthritis (OA) is a major cause of disability in the US, with no approved treatments to slow progression, but animal models suggest that pulsed low-intensity ultrasonography (PLIUS) may promote...
3.
Bekele D, Cheng E, Reimold A, Geier C, Ganuthula K, Walsh J, et al.
Rheumatol Int
. 2021 Nov;
42(11):1925-1937.
PMID: 34724089
Although tumor necrosis factor inhibitors (TNFi) have favorably altered the treatment landscape for patients with axial spondyloarthritis (axSpA), there is limited data regarding TNFi persistence and reasons for discontinuation. This...
4.
Walsh J, Pei S, Penmetsa G, Overbury R, Clegg D, Sauer B
J Rheumatol
. 2020 Dec;
48(5):685-692.
PMID: 33259327
Objective: Observational research of axial spondyloarthritis (axSpA) is limited by a lack of methods for identifying diverse axSpA phenotypes in large datasets. Algorithms were previously designed to identify a broad...
5.
Walsh J, Pei S, Penmetsa G, Sauer B, Patil V, Walker J, et al.
J Manag Care Spec Pharm
. 2019 Oct;
25(11):1218-1228.
PMID: 31663467
Background: Delays in treatment for inflammatory arthritis (IA) are associated with unfavorable outcomes, including impaired quality of life, irreversible joint damage, and disability. Objective: To characterize treatment initiation patterns in...
6.
Walsh J, Pei S, Penmetsa G, Hansen J, Cannon G, Clegg D, et al.
J Rheumatol
. 2019 Mar;
47(1):42-49.
PMID: 30877217
Objective: Observational axial spondyloarthritis (axSpA) research in large datasets has been limited by a lack of adequate methods for identifying patients with axSpA, because there are no billing codes in...
7.
Walsh J, Jones H, Mallbris L, Callis Duffin K, Krueger G, Clegg D, et al.
Psoriasis (Auckl)
. 2018 Oct;
8:65-74.
PMID: 30324088
Background: The product of Physician Global Assessment and Body Surface Area (PGA × BSA) is a new outcome measure for psoriasis severity and response to therapy. The objective of this...
8.
Walsh J, Pei S, Penmetsa G, Leng J, Cannon G, Clegg D, et al.
BMC Musculoskelet Disord
. 2018 Sep;
19(1):317.
PMID: 30185185
Background: Big data research is important for studying uncommon diseases in real-world settings. Most big data studies in axial spondyloarthritis (axSpA) have been limited to populations identified with billing codes...
9.
Velarde K, Romesser J, Johnson M, Clegg D, Efimova O, Oostema S, et al.
Contemp Clin Trials Commun
. 2018 Jul;
11:107-112.
PMID: 30035242
Background: Randomized clinical trials are the gold standard for evaluating healthcare interventions and, more generally, add to the medical knowledge related to the treatment, diagnosis and prevention of diseases and...
10.
Walsh J, Pei S, Burningham Z, Penmetsa G, Cannon G, Clegg D, et al.
J Rheumatol
. 2017 Nov;
45(3):430-436.
PMID: 29142040
Objective: To evaluate the effect of access to and distance from rheumatology care on the use of disease-modifying antirheumatic drugs (DMARD) in US veterans with inflammatory arthritis (IA). Methods: Provider...